216 related articles for article (PubMed ID: 29152775)
1. New insights into diagnosis and therapeutic options for proliferative hepatoblastoma.
Hooks KB; Audoux J; Fazli H; Lesjean S; Ernault T; Dugot-Senant N; Leste-Lasserre T; Hagedorn M; Rousseau B; Danet C; Branchereau S; Brugières L; Taque S; Guettier C; Fabre M; Rullier A; Buendia MA; Commes T; Grosset CF; Raymond AA
Hepatology; 2018 Jul; 68(1):89-102. PubMed ID: 29152775
[TBL] [Abstract][Full Text] [Related]
2. Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma.
Beck A; Eberherr C; Hagemann M; Cairo S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
Cancer Biol Ther; 2016 Nov; 17(11):1168-1176. PubMed ID: 27635950
[TBL] [Abstract][Full Text] [Related]
3. Isoorientin triggers apoptosis of hepatoblastoma by inducing DNA double-strand breaks and suppressing homologous recombination repair.
Huang D; Jin L; Li Z; Wu J; Zhang N; Zhou D; Ni X; Hou T
Biomed Pharmacother; 2018 May; 101():719-728. PubMed ID: 29524880
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
Carrillo-Reixach J; Torrens L; Simon-Coma M; Royo L; Domingo-Sàbat M; Abril-Fornaguera J; Akers N; Sala M; Ragull S; Arnal M; Villalmanzo N; Cairo S; Villanueva A; Kappler R; Garrido M; Guerra L; Sábado C; Guillén G; Mallo M; Piñeyro D; Vázquez-Vitali M; Kuchuk O; Mateos ME; Ramírez G; Santamaría ML; Mozo Y; Soriano A; Grotzer M; Branchereau S; de Andoin NG; López-Ibor B; López-Almaraz R; Salinas JA; Torres B; Hernández F; Uriz JJ; Fabre M; Blanco J; Paris C; Bajčiová V; Laureys G; Masnou H; Clos A; Belendez C; Guettier C; Sumoy L; Planas R; Jordà M; Nonell L; Czauderna P; Morland B; Sia D; Losic B; Buendia MA; Sarrias MR; Llovet JM; Armengol C
J Hepatol; 2020 Aug; 73(2):328-341. PubMed ID: 32240714
[TBL] [Abstract][Full Text] [Related]
5. Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated into mice following treatment with adriamycin or cisplatin.
Bader P; Fuchs J; Wenderoth M; von Schweinitz D; Niethammer D; Beck JF
Anticancer Res; 1998; 18(4C):3127-32. PubMed ID: 9713521
[TBL] [Abstract][Full Text] [Related]
6. The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model.
Warmann S; Hunger M; Teichmann B; Flemming P; Gratz KF; Fuchs J
Cancer; 2002 Oct; 95(8):1795-801. PubMed ID: 12365029
[TBL] [Abstract][Full Text] [Related]
7. A combined clinical and biological risk classification improves prediction of outcome in hepatoblastoma patients.
Cairo S; Armengol C; Maibach R; Häberle B; Becker K; Carrillo-Reixach J; Guettier C; Vokuhl C; Schmid I; Buendia MA; Branchereau S; von Schweinitz D; Kappler R
Eur J Cancer; 2020 Dec; 141():30-39. PubMed ID: 33125945
[TBL] [Abstract][Full Text] [Related]
8. Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups.
Sumazin P; Chen Y; Treviño LR; Sarabia SF; Hampton OA; Patel K; Mistretta TA; Zorman B; Thompson P; Heczey A; Comerford S; Wheeler DA; Chintagumpala M; Meyers R; Rakheja D; Finegold MJ; Tomlinson G; Parsons DW; López-Terrada D
Hepatology; 2017 Jan; 65(1):104-121. PubMed ID: 27775819
[TBL] [Abstract][Full Text] [Related]
9. Potential therapies for residual hepatoblastoma following incomplete ablation treatment in a nude mouse subcutaneous xenograft model based on lncRNA and mRNA expression profiles.
Wang XD; Peng JB; Zhou CY; Que Q; Li HY; He Y; Yang H
Oncol Rep; 2020 Jun; 43(6):1915-1927. PubMed ID: 32186781
[TBL] [Abstract][Full Text] [Related]
10. Ginsenoside Rg1 impairs homologous recombination repair by targeting CtBP-interacting protein and sensitizes hepatoblastoma cells to DNA damage.
Zhen N; Jin L; Ma J; Zhu J; Gu S; Wang J; Pan Q; Ni X; Xu M
Anticancer Drugs; 2018 Sep; 29(8):756-766. PubMed ID: 29952772
[TBL] [Abstract][Full Text] [Related]
11. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
12. Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex.
Jia D; Dong R; Jing Y; Xu D; Wang Q; Chen L; Li Q; Huang Y; Zhang Y; Zhang Z; Liu L; Zheng S; Xia Q; Wang H; Dong K; He X
Hepatology; 2014 Nov; 60(5):1686-96. PubMed ID: 24912477
[TBL] [Abstract][Full Text] [Related]
13. Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737.
Lieber J; Dewerth A; Wenz J; Kirchner B; Eicher C; Warmann SW; Fuchs J; Armeanu-Ebinger S
Oncol Rep; 2013 Feb; 29(2):646-52. PubMed ID: 23229825
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of survivin in hepatoblastoma after chemotherapy.
Uehara S; Oue T; Kawatsu M; Nara K; Fukuzawa M
Eur J Pediatr Surg; 2013 Oct; 23(5):400-4. PubMed ID: 23444076
[TBL] [Abstract][Full Text] [Related]
15. General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.
Lee H; El Jabbour T; Ainechi S; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon SH; Ali SM; Schrock A; Fabrizio D; Frampton G; Nazeer T; Miller VA; Stephens PJ; Ross JS
Hum Pathol; 2017 Dec; 70():84-91. PubMed ID: 29079173
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of
Liu L; Cui Z; Zhang J; Wang J; Gu S; Ma J; Chen H; Hang L; Yang J; Shi Y
Cancer Biother Radiopharm; 2020 Feb; 35(1):41-49. PubMed ID: 31916845
[No Abstract] [Full Text] [Related]
17. Alternative Splicing of lncRNAs From SNHG Family Alters snoRNA Expression and Induces Chemoresistance in Hepatoblastoma.
Zhen N; Zhu J; Mao S; Zhang Q; Gu S; Ma J; Zhang Y; Yin M; Li H; Huang N; Wu H; Sun F; Ying B; Zhou L; Pan Q
Cell Mol Gastroenterol Hepatol; 2023; 16(5):735-755. PubMed ID: 37478905
[TBL] [Abstract][Full Text] [Related]
18. Targeting G9a/DNMT1 methyltransferase activity impedes IGF2-mediated survival in hepatoblastoma.
Demir S; Razizadeh N; Indersie E; Branchereau S; Cairo S; Kappler R
Hepatol Commun; 2024 Feb; 8(2):. PubMed ID: 38285887
[TBL] [Abstract][Full Text] [Related]
19. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma.
Clavería-Cabello A; Herranz JM; Latasa MU; Arechederra M; Uriarte I; Pineda-Lucena A; Prosper F; Berraondo P; Alonso C; Sangro B; García Marin JJ; Martinez-Chantar ML; Ciordia S; Corrales FJ; Francalanci P; Alaggio R; Zucman-Rossi J; Indersie E; Cairo S; Domingo-Sàbat M; Zanatto L; Sancho-Bru P; Armengol C; Berasain C; Fernandez-Barrena MG; Avila MA
J Hepatol; 2023 Oct; 79(4):989-1005. PubMed ID: 37302584
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients.
Wagner F; Henningsen B; Lederer C; Eichenmüller M; Gödeke J; Müller-Höcker J; von Schweinitz D; Kappler R
Eur J Cancer; 2012 Oct; 48(15):2442-50. PubMed ID: 22285179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
